27.90

0.07% +0.02

After Hours: 27.88 -0.02 -0.07%

vTv Therapeutics Inc (VTVT)

Overview News Price History Financials Discussions Forecast

vTv Therapeutics Inc stock is currently priced at $27.90, with a 24-hour trading volume of 6,628. It has seen a +0.07% increased in the last 24 hours and a +15.53% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $27.19 pivot point. If it approaches the $28.57 resistance level, significant changes may occur.

Previous Close:

$27.88

Open:

$26.12

24h Volume:

6,628

Market Cap:

$67.88M

Revenue:

$5.02M

Net Income/Loss:

$-20.25M

P/E Ratio:

-116.25

EPS:

-0.24

Net Cash Flow:

$-19.08M

1W Performance:

+7.35%

1M Performance:

+15.53%

6M Performance:

+7,416%

1Y Performance:

+2,845%

1D Range:

$25.50

$27.90

52W Range:

$0.35

$30.99

vTv Therapeutics Inc Stock (VTVT) Company Profile

Name

vTv Therapeutics Inc

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

336-841-0300

Address

4170 Mendenhall Oaks Parkway, High Point, NC

Employee

Twitter

@vTvTherapeutics

Next Earnings Date

2024-06-11

Latest SEC Filings

VTVT's Discussions on Twitter

vTv Therapeutics Inc Stock (VTVT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-30-19	Initiated	H.C. Wainwright	Buy
Apr-10-18	Downgrade	Stifel	Buy → Hold
Mar-08-18	Initiated	ROTH Capital	Buy
Feb-08-18	Initiated	Northland Capital	Outperform
Sep-26-16	Initiated	H.C. Wainwright	Buy
Sep-04-15	Initiated	Canaccord Genuity	Buy
Aug-24-15	Initiated	Piper Jaffray	Overweight
Aug-24-15	Initiated	Stifel	Buy

View All

vTv Therapeutics Inc Stock (VTVT) Latest News

Trading (VTVT) With Integrated Risk Controls - Stock Traders Daily

Stock Traders Daily

VTv Therapeutics (VTVT) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Movies UK

Yahoo Movies UK

vTv Therapeutics (NASDAQ:VTVT shareholders incur further losses as stock declines 17% this week, taking five-year ... - Yahoo New Zealand News

Yahoo New Zealand News

vTv Therapeutics Inc Stock (VTVT) Financials Data

vTv Therapeutics Inc (VTVT) Revenue 2024

VTVT reported a revenue (TTM) of $5.02 million for the quarter ending June 30, 2022, a -32.21% decline year-over-year.

vTv Therapeutics Inc (VTVT) Net Income 2024

VTVT net income (TTM) was -$20.25 million for the quarter ending December 31, 2023, a -5.67% decrease year-over-year.

vTv Therapeutics Inc (VTVT) Cash Flow 2024

VTVT recorded a free cash flow (TTM) of -$19.08 million for the quarter ending December 31, 2023, a -18.94% decrease year-over-year.

vTv Therapeutics Inc (VTVT) Earnings per Share 2024

VTVT earnings per share (TTM) was -$9.71 for the quarter ending December 31, 2023, a +2.90% growth year-over-year.

vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide. The company's drug candidates comprise azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials for the treatment of Alzheimer's disease. Its drug candidates also include TTP399, an orally administered, liver-selective glucokinase activator that has completed Phase 2b clinical trials for the treatment of type 2 diabetes, as well as initiated Phase 1b/2 clinical trials for the treatment of type 1 diabetes; and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor, which has completed Phase II clinical trials for the treatment of type 2 diabetes. vTv Therapeutics Inc. has a license and research agreement with Calithera Biosciences, Inc. to develop and commercialize its hexokinase II inhibitors for therapeutic, prophylactic, preventative, or diagnostic use. The company was founded in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of vTv Therapeutics Holdings LLC.